Canntab Therapeutics

Overview

Canntab Therapeutics (CSE:PILL, OTC:CTABF, FSE:TBF1) is bringing pharmaceutical expertise to the cannabis market through the development of its patent-pending Canntab Extended Release (XR) Tablets™. Using proprietary extended release technology previously developed by the company, Canntab is producing a safe, stable and standardized delivery method for cannabis particles (CBD and THC) that is not burdened with the negative effects associated with smoking, edibles or topicals.

The proprietary extended release technology provides lasting effects of 12 to 18 hours, making the Canntab XR Tablets™ an appealing alternative to other intake methods. The XR Tablets™ have also been designed for doses of 2.5 mg, 5.0 mg or 10.0 mg, making dosing and prescribing much more straightforward for the medical community.

Based in Markham, Ontario, Canntab has also entered into a licensing agreement with Emblem Corp, a licensed producer (LP), under which Emblem will develop and market Canntab’s XR Tablets™ in Canada. Beyond Canada, Canntab has entered into a joint venture with Vitacann, a subsidiary of Queensland Bauxite (ASX:QBL), under which the companies will work towards the approval of sales of Canntab XR Tablets™ in Australia as well as their export to Asia. Canntab has also signed non-binding Letters of Intent with NewCanna S.A.S Bogota in Columbia and Labsco Promedic SA in Mexico, covering the sale and distribution in Columbia, Chile, Paraguay, Spain and Mexico.

Canntab is led by a management team with proven experience in both the pharmaceutical and capital market spaces. The company’s leaders, Jeff Renwick and Richard Goldstein, have been working with their team to develop Canntab’s proprietary technology for almost a decade and have numerous patents for unique drug formulations, making them leaders within the cannabis pharmaceutical space. The management team is also supported by board members Vitor Fonseca and Sheldon Inwentash, both of which provide extensive insight into financial aspects and business development.

Canntab Therapeutics Highlights

• Proprietary Canntab XR Tablets™ provide safe, fast-acting and long-lasting alternative to current cannabis intake methods
• A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. The products will be available in 2.5g, 5g and 10g tablets.
• An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.
• Licensing agreement with Emblem Corp, leading Canadian LP to develop and market XR Tablets™
• Reaching a milestone in its development of a patent-pending oral extended release formulation for cannabinoids in collaboration with Emblem Corp. (TSXV:EMC, OTCQX:EMMBF). Dissolution testing indicated that the Extended Release Tablets released cannabinoids consistently over a 12-hour period. Given these positive test results, Canntab is manufacturing pivotal batches of these tablets for further clinical testing. This will lead to the filing of dossiers with regulatory agencies around the world for approval of Canntab’s unique solid oral dose delivery systems.
• Co-locating in 10,000-square-foot area within the FSD Pharma facility in Cobourg, Ontario for production and distribution of products
• Health Canada’s approval of Canntab’s ‘420 Therapeutics’ brand of Cannabis wellness products. These capsules are made with purified organic hemp seed oil and are an easy and convenient way to enjoy the health benefits of hemp oil. This is an important milestone achievement for Canntab in their move towards manufacturing full spectrum hemp derived CBD.
• Entered into joint venture with Australian company Vitacann, seeking approval for sale of Canntab XR Tablets™ within Australia and export to Asia